Phaseline

Targets › GRIA3

GRIA3 (Glutamate receptor 3): drug programs, companies and trials

5 programs from 5 companies in 16 trials: 5 Phase 3, 4 Phase 1, 4 Phase 4, 3 Phase 2; Psychiatry, Neurology, Metabolic and endocrine; next expected readout Apr 2027.

Ionotropic glutamate receptor that functions as a ligand-gated cation channel, gated by L-glutamate and glutamatergic agonists such as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), quisqualic acid, and kainic acid (By similarity). L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system and plays an important role in fast excitatory synaptic transmission by…. (UniProt, P42263)

Open in Phaseline: the race on GRIA3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Upsher-Smith LaboratoriesTopiramate
Carbonic anhydrase II inhibitor; Carbonic anhydrase IV inhibitor; Glutamate receptor ionotropic AMPA antagonist
CA2, CA4, GRIA4, GRIA3, GRIA2Phase 4Migraine Disorders; Obesity; Ménière; Liver Cirrhoses …–
Neurocrine BiosciencesOsavampator (NBI-1065845)
Glutamate receptor ionotropic AMPA positive allosteric modulator
GRIA4, GRIA3, GRIA2, GRIA1Phase 3Major Depressive DisorderJul 2027
EisaiPerampanel
Glutamate receptor ionotropic AMPA antagonist
GRIA4, GRIA3, GRIA2, GRIA1Phase 2Pediatric Epileptic Syndrome; Depressive Disorder; Depression; Depressive Disorder, MajorApr 2027
PronirasTezampanel
Glutamate receptor ionotropic AMPA antagonist; Glutamate receptor ionotropic kainate antagonist
GRIA4, GRIA3, GRIA2, GRIA1, GRIK1Phase 1Opioid Use DisorderOct 2027
Carolyn RodriguezRR-HNK/Hydroxynorketamine
AMPA receptor antagonist
GRIA1, GRIA2, GRIA3Phase 1Obsessive-Compulsive DisorderNov 2028

Conditions

Major Depressive Disorder (5) Pediatric Epileptic Syndrome (1) Depressive Disorder (1) Depression (1) Depressive Disorder, Major (1) Migraine Disorders (1) Obesity (1) Ménière (1) Liver Cirrhoses (1) Post Traumatic Stress Disorder (1) Obsessive-Compulsive Disorder (1) Opioid Use Disorder (1)

Modalities

small molecule (5)

Companies

Neurocrine Biosciences (1) Eisai (1) Upsher-Smith Laboratories (1) Carolyn Rodriguez (1) Proniras (1)

Related targets

GRIA2 (5) GRIA4 (4) GRIA1 (4) CA2 (1) CA4 (1) GRIK1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.